{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:37:35Z","timestamp":1777279055673,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001266","name":"Action Duchenne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011724","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008164","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008164","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.bone.2025.117410","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:20:34Z","timestamp":1737692434000},"page":"117410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacological and non-pharmacological therapies for prevention and treatment of osteoporosis in Duchenne Muscular Dystrophy: A systematic review"],"prefix":"10.1016","volume":"193","author":[{"given":"Sarah","family":"McCarrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shima","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ros","family":"Quinlivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze Choong","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of duchenne muscular dystrophy: current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.bone.2025.117410_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/928385","article-title":"Optimizing bone health in Duchenne muscular dystrophy","volume":"2015","author":"Buckner","year":"2015","journal-title":"Int. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"9","key":"10.1016\/j.bone.2025.117410_bb0020","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0883073810371004","article-title":"Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management","volume":"25","author":"Moxley","year":"2010","journal-title":"J. Child Neurol."},{"issue":"3","key":"10.1016\/j.bone.2025.117410_bb0025","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bone.2025.117410_bb0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.2002.tb04204.x","article-title":"Mechanisms of glucocorticoid action in bone","volume":"966","author":"Canalis","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.bone.2025.117410_bb0035","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: results from the UK NorthStar database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nmd.2018.09.005","article-title":"Fractures and bone health monitoring in boys with Duchenne muscular dystrophy managed within the Scottish Muscle Network","volume":"29","author":"Joseph","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"19","key":"10.1016\/j.bone.2025.117410_bb0045","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J. Pediatr. Orthop."},{"issue":"10","key":"10.1016\/j.bone.2025.117410_bb0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1469-8749.2002.tb00272.x","article-title":"Fracture prevalence in Duchenne muscular dystrophy","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev. Med. Child Neurol."},{"issue":"4","key":"10.1016\/j.bone.2025.117410_bb0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/000992280304200408","article-title":"Vertebral fractures in boys with Duchenne muscular dystrophy","volume":"42","author":"Bothwell","year":"2003","journal-title":"Clin. Pediatr. (Phila)"},{"issue":"4","key":"10.1016\/j.bone.2025.117410_bb0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bone.2025.117410_bb0070","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3389\/fendo.2020.00576","article-title":"Glucocorticoid-induced osteoporosis: why kids are different","volume":"11","author":"Ward","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/clinem\/dgad435","article-title":"Risk factors associated with incident vertebral fractures in steroid-treated males with Duchenne muscular dystrophy","volume":"109","author":"Phung","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bone.2025.117410_bb0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11914-010-0031-2","article-title":"Biomechanics of vertebral fractures and the vertebral fracture cascade","volume":"8","author":"Christiansen","year":"2010","journal-title":"Curr. Osteoporos. Rep."},{"issue":"9","key":"10.1016\/j.bone.2025.117410_bb0085","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JND-230176","article-title":"Moving beyond the 2018 minimum international care considerations for osteoporosis Management in Duchenne Muscular Dystrophy (DMD): meeting report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022","volume":"11","author":"Phung","year":"2024","journal-title":"J Neuromuscul Dis."},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0095","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207948","article-title":"Bisphosphonates in glucocorticoid-treated patients with Duchenne muscular dystrophy: a systematic review and grading of the evidence","volume":"102","author":"Landfeldt","year":"2024","journal-title":"Neurology"},{"issue":"11\u221212","key":"10.1016\/j.bone.2025.117410_bb0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.nmd.2007.05.008","article-title":"Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy","volume":"17","author":"S\u00f6derpalm","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bone.2025.117410_bb0105","article-title":"Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy","volume":"1(1):Cd010899","author":"Bell","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2025.117410_bb0110","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.bone.2025.117410_bb0115","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.bone.2025.117410_bb0120","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.bone.2025.117410_bb0125","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1210\/clinem\/dgab302","article-title":"Randomized controlled trial evaluating the use of Zoledronic acid in Duchenne muscular dystrophy","volume":"106","author":"Zacharin","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0130","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4158\/EP-2020-0073","article-title":"Effects of bisphosphonates on osteoporosis induced by Duchenne muscular dystrophy: a prospective study","volume":"26","author":"Zheng","year":"2020","journal-title":"Endocr. Pract."},{"issue":"5","key":"10.1016\/j.bone.2025.117410_bb0135","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/jbmr.2756","article-title":"Histomorphometry and bone matrix mineralization before and after bisphosphonate treatment in boys with Duchenne muscular dystrophy: a paired Transiliac biopsy study","volume":"31","author":"Misof","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0140","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch. Phys. Med. Rehabil."},{"issue":"7","key":"10.1016\/j.bone.2025.117410_bb0145","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s12325-022-02179-1","article-title":"Effectiveness of neridronate in the management of bone loss in patients with Duchenne muscular dystrophy: results from a pilot study","volume":"39","author":"Moretti","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bone.2025.117410_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/1179551420972400","article-title":"Effects of bisphosphonate therapy on bone mineral density in boys with Duchenne muscular dystrophy","volume":"13","author":"Ronsley","year":"2020","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"issue":"7","key":"10.1016\/j.bone.2025.117410_bb0155","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nmd.2020.06.005","article-title":"Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy","volume":"30","author":"Tian","year":"2020","journal-title":"Neuromuscul. Disord."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.bone.2025.117410_bb0165","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.23948","article-title":"Bone density and alendronate effects in Duchenne muscular dystrophy patients","volume":"49","author":"Houston","year":"2014","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.bone.2025.117410_bb0170","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.bone.2025.117410_bb0175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mus.27416","article-title":"The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis","volume":"64","author":"Nasomyont","year":"2021","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0180","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jpc.13692","article-title":"Therapeutic options to improve bone health outcomes in Duchenne muscular dystrophy: Zoledronic acid and pubertal induction","volume":"53","author":"Lim","year":"2017","journal-title":"J. Paediatr. Child Health"},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0185","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000508290","article-title":"Effect of testosterone treatment for delayed puberty in Duchenne muscular dystrophy","volume":"93","author":"Lee","year":"2020","journal-title":"Horm. Res. Paediatr."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0190","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-20-0709","article-title":"Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area","volume":"184","author":"Wood","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0195","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0245","article-title":"Is ongoing testosterone required after pubertal induction in Duchenne muscular dystrophy?","volume":"12","author":"Wood","year":"2023","journal-title":"Endocr Connect."},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0200","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1007\/s00198-020-05549-z","article-title":"Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy","volume":"31","author":"Nasomyont","year":"2020","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0205","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00198-010-1275-5","article-title":"Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment","volume":"22","author":"Bianchi","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"11","key":"10.1016\/j.bone.2025.117410_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10685","article-title":"Low-intensity vibration protects the weight-bearing skeleton and suppresses fracture incidence in boys with Duchenne muscular dystrophy: a prospective, randomized, double-blind, placebo-controlled clinical trial","volume":"6","author":"Bianchi","year":"2022","journal-title":"JBMR Plus."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0215","first-page":"13","article-title":"Whole body vibration therapy in patients with Duchenne muscular dystrophy--a prospective observational study","volume":"13","author":"S\u00f6derpalm","year":"2013","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0220","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.nmd.2021.09.007","article-title":"The impact of testosterone therapy on quality of life in adolescents with Duchenne muscular dystrophy","volume":"31","author":"Wood","year":"2021","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.bone.2025.117410_bb0225","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0230","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"J. Pediatr."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0235","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.CC.21.00664","article-title":"Effect of Denosumab on bone health in adult patients with Duchenne\/Becker muscular dystrophy: a report of 2 cases","volume":"12","author":"Hung","year":"2022","journal-title":"JBJS Case Connect"},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0240","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.CC.17.00190","article-title":"Efficacy of Denosumab for glucocorticoid-induced osteoporosis in an adolescent patient with Duchenne muscular dystrophy: a case report","volume":"8","author":"Kumaki","year":"2018","journal-title":"JBJS Case Connect."},{"issue":"4","key":"10.1016\/j.bone.2025.117410_bb0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00223-023-01116-w","article-title":"Anti-RANKL therapy prevents glucocorticoid-induced bone loss and promotes muscle function in a mouse model of Duchenne muscular dystrophy","volume":"113","author":"Jayash","year":"2023","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2025.117410_bb0250","series-title":"RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy. Cells","volume":"12(11)","author":"Marcadet","year":"2023"},{"issue":"11","key":"10.1016\/j.bone.2025.117410_bb0255","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2014-3072","article-title":"Effect of denosumab on the growing skeleton in osteogenesis imperfecta","volume":"99","author":"Hoyer-Kuhn","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2025.117410_bb0260","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/jc.2013-3081","article-title":"Effects of denosumab treatment and discontinuation on human growth plates","volume":"99","author":"Wang","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"20","key":"10.1016\/j.bone.2025.117410_bb0265","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0270","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1007\/s00198-016-3761-x","article-title":"Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report","volume":"27","author":"Catalano","year":"2016","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.bone.2025.117410_bb0275","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10665","article-title":"Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates","volume":"6","author":"Krege","year":"2022","journal-title":"JBMR Plus."},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials","volume":"21","author":"Liu","year":"2018","journal-title":"Climacteric"},{"issue":"16","key":"10.1016\/j.bone.2025.117410_bb0285","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2025.117410_bb0290","first-page":"458","article-title":"Frequency of delayed puberty in boys with contemporary management of Duchenne Muscular Dystrophy","volume":"16","author":"McCarrison","year":"2024","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"2","key":"10.1016\/j.bone.2025.117410_bb0295","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-023-06951-z","article-title":"Growth hormone and testosterone delay vertebral fractures in boys with muscular dystrophy on chronic glucocorticoids","volume":"35","author":"Loscalzo","year":"2024","journal-title":"Osteoporos. Int."},{"issue":"12","key":"10.1016\/j.bone.2025.117410_bb0300","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.nmd.2012.07.009","article-title":"Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure","volume":"22","author":"Rutter","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.bone.2025.117410_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2023.101558","article-title":"Growth hormone therapy for children with Duchenne muscular dystrophy and glucocorticoid induced short stature","volume":"72-73","author":"Lavi","year":"2023","journal-title":"Growth Horm. IGF Res."},{"issue":"8","key":"10.1016\/j.bone.2025.117410_bb0310","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/jbmr.3718","article-title":"Growth hormone increases bone toughness and decreases muscle inflammation in glucocorticoid-treated mdx mice, model of Duchenne Muscular Dystrophy","volume":"34","author":"Yoon","year":"2019","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2025.117410_bb0315","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mus.26846","article-title":"Recombinant human insulin-like growth factor-1 therapy for 6months improves growth but not motor function in boys with Duchenne muscular dystrophy","volume":"61","author":"Rutter","year":"2020","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.bone.2025.117410_bb0320","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJMra1614394","article-title":"Evidence for health decision making - beyond randomized, controlled trials","volume":"377","author":"Frieden","year":"2017","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.bone.2025.117410_bb0325","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1740774520958395","article-title":"A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians","volume":"18","author":"Choong Wong","year":"2021","journal-title":"Clin. Trials"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T07:42:08Z","timestamp":1777275728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":65,"alternative-id":["S8756328225000225"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117410","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological and non-pharmacological therapies for prevention and treatment of osteoporosis in Duchenne Muscular Dystrophy: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117410"}}